NasdaqGM:ESPR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. More Details


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has Esperion Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ESPR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.2%

ESPR

-2.8%

US Biotechs

-5.3%

US Market


1 Year Return

-26.9%

ESPR

22.7%

US Biotechs

10.4%

US Market

Return vs Industry: ESPR underperformed the US Biotechs industry which returned 25% over the past year.

Return vs Market: ESPR underperformed the US Market which returned 12% over the past year.


Shareholder returns

ESPRIndustryMarket
7 Day-7.2%-2.8%-5.3%
30 Day-16.2%-2.6%-2.1%
90 Day-20.4%-2.5%1.7%
1 Year-26.9%-26.9%24.9%22.7%12.9%10.4%
3 Year-37.1%-37.1%14.3%8.6%34.3%25.4%
5 Year7.9%7.9%5.7%-2.0%73.7%54.3%

Price Volatility Vs. Market

How volatile is Esperion Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Esperion Therapeutics undervalued compared to its fair value and its price relative to the market?

34.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ESPR ($29.97) is trading below our estimate of fair value ($45.77)

Significantly Below Fair Value: ESPR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ESPR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ESPR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ESPR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ESPR is overvalued based on its PB Ratio (9.7x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

22.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ESPR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ESPR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ESPR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ESPR's revenue (24.8% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: ESPR's revenue (24.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Esperion Therapeutics performed over the past 5 years?

-18.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ESPR is currently unprofitable.

Growing Profit Margin: ESPR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ESPR is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.

Accelerating Growth: Unable to compare ESPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ESPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).


Return on Equity

High ROE: ESPR has a negative Return on Equity (-98.21%), as it is currently unprofitable.


Next Steps

Financial Health

How is Esperion Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ESPR's short term assets ($321.4M) exceed its short term liabilities ($83.9M).

Long Term Liabilities: ESPR's short term assets ($321.4M) exceed its long term liabilities ($161.0M).


Debt to Equity History and Analysis

Debt Level: ESPR's debt to equity ratio (194.5%) is considered high.

Reducing Debt: ESPR's debt to equity ratio has increased from 1.6% to 194.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ESPR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ESPR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ESPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Tim Mayleben (59 yo)

7.83yrs

Tenure

US$1,080,850

Compensation

Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biote ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD1.08M) is below average for companies of similar size in the US market ($USD2.96M).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Mayleben
President7.83yrsUS$1.08m0.32%
$ 2.7m
Richard Bartram
CFO & Corporate Secretary2.75yrsUS$485.50k0.040%
$ 332.4k
Mark Glickman
Chief Commercial Officer2.42yrsUS$624.39k0.031%
$ 262.3k
Kenneth Fiorelli
Chief Technical Operations Officer1yrno datano data
Alexander Schwartz
Senior Director of Investor Relations2.42yrsno datano data
Keith Lenden
Vice President of Corporate Development & Strategyno datano datano data
Renee Marotta
Head of Marketingno datano datano data
Ashley Hall
Chief Development Officer2.42yrsno data0.036%
$ 299.7k
April Seiler
Senior Director of Project Management12.42yrsno datano data
Roberta Peterson
Senior Director of National Accountsno datano datano data
Jerry Penn
Executive Director of Managed Care2.25yrsno datano data

2.4yrs

Average Tenure

48yo

Average Age

Experienced Management: ESPR's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Timothy Mayleben
President7.83yrsUS$1.08m0.32%
$ 2.7m
Daniel Janney
Independent Director7.83yrsUS$300.00k0.018%
$ 148.9k
Nicole Vitullo
Lead Independent Director4.83yrsUS$327.50k0.048%
$ 398.2k
Alan Fuhrman
Independent Non-Employee Director0.58yrno data0.046%
$ 385.9k
Antonio Gotto
Independent Director6.75yrsUS$295.00k0.040%
$ 331.8k
Jay Shepard
Independent Director2.42yrsUS$308.39k0.040%
$ 331.8k
Jeffrey Berkowitz
Director2.83yrsUS$297.50k0.040%
$ 331.8k
Tracy Woody
Independent Director1.42yrsUS$513.36k0.011%
$ 90.6k
Mark McGovern
Independent Director6.58yrsUS$295.00k0.036%
$ 298.7k

4.8yrs

Average Tenure

62yo

Average Age

Experienced Board: ESPR's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.


Top Shareholders

Company Information

Esperion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Esperion Therapeutics, Inc.
  • Ticker: ESPR
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$833.928m
  • Shares outstanding: 27.83m
  • Website: https://www.esperion.com

Number of Employees


Location

  • Esperion Therapeutics, Inc.
  • 3891 Ranchero Drive
  • Suite 150
  • Ann Arbor
  • Michigan
  • 48108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ESPRNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2013
0ETDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2013
0IIMLSE (London Stock Exchange)YesCommon StockGBUSDJun 2013

Biography

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States. Its lead p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/31 00:01
End of Day Share Price2020/10/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.